INVO Bioscience, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on January 15, 2022. The report details the approval of compensatory arrangements for non-employee directors and executive officers under the Company's 2019 Stock Incentive Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data point disclosed is the closing stock price of $3.61 per share on January 14, 2022, which was used to calculate equity grant values.
Material Changes and Compensation Details
The Board approved the following compensation structures effective January 15, 2022:
- Non-Employee Directors:
- Base Compensation: $25,000 cash retainer, $25,000 stock grant, and options to purchase $25,000 worth of stock.
- Committee Chairs: Additional $12,500 cash, $5,000 stock grant, and $5,000 options.
- Committee Members: Additional $5,000 cash, $2,000 stock grant, and $2,000 options.
- Terms: Options vest monthly over one year, have a 10-year term, and an exercise price of $3.61.
- Executive Officers (2021 Equity Bonus):
- Steve Shum (CEO): 20,111 shares and options for 57,018 shares.
- Michael Campbell (COO): 15,236 shares and options for 18,513 shares.
- Andrea Goren (CFO): 5,361 shares and options for 15,197 shares.
- Terms: Options vest monthly over three years, have a 10-year term, and an exercise price of $3.61.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks and contingencies beyond the standard disclosure of the compensation plan terms.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2019 Stock Incentive Plan to assess remaining capacity for future grants.
- Confirm the dilution impact of the specific share counts granted to executives and directors.
- Review the vesting schedules to understand future expense recognition for stock-based compensation.
- Check subsequent filings for any changes to the $3.61 exercise price or stock price performance relative to the grant date.